286 related articles for article (PubMed ID: 32862830)
1. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.
Kwak S; Choi J; Hink T; Reske KA; Blount K; Jones C; Bost MH; Sun X; Burnham CD; Dubberke ER; Dantas G;
Microbiome; 2020 Aug; 8(1):125. PubMed ID: 32862830
[TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
4. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
5. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
6. Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic.
Blount KF; Shannon WD; Deych E; Jones C
Open Forum Infect Dis; 2019 Apr; 6(4):ofz095. PubMed ID: 31024971
[TBL] [Abstract][Full Text] [Related]
7. A microbial consortium alters intestinal
Rooney AM; Cochrane K; Fedsin S; Yao S; Anwer S; Dehmiwal S; Hota S; Poutanen S; Allen-Vercoe E; Coburn B;
mBio; 2023 Aug; 14(4):e0348222. PubMed ID: 37404011
[TBL] [Abstract][Full Text] [Related]
8. The infant gut resistome is associated with E. coli and early-life exposures.
Lebeaux RM; Coker MO; Dade EF; Palys TJ; Morrison HG; Ross BD; Baker ER; Karagas MR; Madan JC; Hoen AG
BMC Microbiol; 2021 Jul; 21(1):201. PubMed ID: 34215179
[TBL] [Abstract][Full Text] [Related]
9. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
10. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
Dubberke ER; Lee CH; Orenstein R; Khanna S; Hecht G; Gerding DN
Clin Infect Dis; 2018 Sep; 67(8):1198-1204. PubMed ID: 29617739
[TBL] [Abstract][Full Text] [Related]
11. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.
Bulow C; Langdon A; Hink T; Wallace M; Reske KA; Patel S; Sun X; Seiler S; Jones S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2018 Nov; 3(6):. PubMed ID: 30463925
[TBL] [Abstract][Full Text] [Related]
12. Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent
Papazyan R; Ferdyan N; Srinivasan K; Gonzalez C; Shannon WD; Blount K; Fuchs BC
Microorganisms; 2023 Jan; 11(1):. PubMed ID: 36677428
[TBL] [Abstract][Full Text] [Related]
13. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
14. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
15. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
16. Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection.
Ray A; Jones C
Future Microbiol; 2016 May; 11():611-6. PubMed ID: 26986546
[TBL] [Abstract][Full Text] [Related]
17. Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study.
Willmann M; Vehreschild MJGT; Biehl LM; Vogel W; Dörfel D; Hamprecht A; Seifert H; Autenrieth IB; Peter S
BMC Biol; 2019 Sep; 17(1):76. PubMed ID: 31533707
[TBL] [Abstract][Full Text] [Related]
18. Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua.
Mills M; Lee S; Piperata BA; Garabed R; Choi B; Lee J
Microbiome; 2023 Sep; 11(1):207. PubMed ID: 37715296
[TBL] [Abstract][Full Text] [Related]
19. Differential response to prolonged amoxicillin treatment: long-term resilience of the microbiome versus long-lasting perturbations in the gut resistome.
Dhariwal A; Haugli Bråten LC; Sturød K; Salvadori G; Bargheet A; Åmdal H; Junges R; Berild D; Zwart JA; Storheim K; Petersen FC
Gut Microbes; 2023; 15(1):2157200. PubMed ID: 36576106
[TBL] [Abstract][Full Text] [Related]
20. Resistome expansion in disease-associated human gut microbiomes.
Fredriksen S; de Warle S; van Baarlen P; Boekhorst J; Wells JM
Microbiome; 2023 Jul; 11(1):166. PubMed ID: 37507809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
